The overall long-term objective of this research program is to develop and investigate novel vaccine approaches for the immunotherapy of malignancy. It is apparent that experimental and human tumors express capable of being recognized by the immune system; however, the innate immunoresponse to progressive tumors is sufficient due to the weakness of the antigen and/or occurrence of tumor-induced immunosuppression. Over the last several years a large body of evidence has accumulated indicating that dendritic cells are highly effective in processing and presenting antigens from a diverse array of tumors to naive T cells which are then capable of inducing tumor rejection responses. The major theme of this program project is the investigation of dendritic cell-based vaccines in the therapy of cancer. This program is comprised of three highly interactive projects and a core support structure as follows: Project by Mule: SLC and Dendritic Cells in Antitumor Immunity and Therapy Project by Chang: Immune Responses Induced by Tumor-Pulsed DC Project by Nickoloff: Dendritic Cell-Based Vaccines in Stage IV Melanoma Patients These projects are oriented toward clinical applications with each one involving experiments therapeutics studies in patients with refractory cancers. The populations which will be evaluated include individuals with melanoma or colorectal cancer. Melanoma represents a tumor which has traditionally been examined in immunotherapeutic trials and appears to represent a weakly immunogenic neoplasm with identified tumor associated antigens. Colorectal cancer is postulated to be a poorly immunogenic tumor and has not been a cancer which has been adequately evaluated for immunotherapy. Inherent in all three projects will be the characterization of the cellular responses associated with dendritic cell- based vaccines. It is anticipated that the information generated from the projects will provide important information about the antigens expressed on these cancers and their immunobiology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA059327-13
Application #
6943919
Study Section
Special Emphasis Panel (ZCA1-GRB-J (J2))
Program Officer
Xie, Heng
Project Start
1992-09-30
Project End
2007-03-31
Budget Start
2005-05-18
Budget End
2007-03-31
Support Year
13
Fiscal Year
2005
Total Cost
$1,536,897
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Surgery
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Teitz-Tennenbaum, Seagal; Li, Qiao; Davis, Mary A et al. (2009) Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. J Immunother 32:602-12
Redman, Bruce G; Chang, Alfred E; Whitfield, Joel et al. (2008) Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother 31:591-8
Teitz-Tennenbaum, Seagal; Li, Qiao; Davis, Mary A et al. (2008) Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model. Clin Immunol 129:482-91
Teitz-Tennenbaum, Seagal; Li, Qiao; Okuyama, Ryuji et al. (2008) Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. J Immunother 31:345-58
Govindarajan, Baskaran; Sligh, James E; Vincent, Bethaney J et al. (2007) Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 117:719-29
Pinnix, Chelsea C; Herlyn, Meenhard (2007) The many faces of Notch signaling in skin-derived cells. Pigment Cell Res 20:458-65
Topczewska, Jolanta M; Postovit, Lynne-Marie; Margaryan, Naira V et al. (2006) Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med 12:925-32
Pilon-Thomas, Shari; Verhaegen, Monique; Kuhn, Lisa et al. (2006) Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells. Cancer Immunol Immunother 55:1238-46
Qin, Jian-Zhong; Xin, Hong; Sitailo, Leonid A et al. (2006) Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res 66:9636-45
Pilon-Thomas, Shari; Li, Wenbin; Briggs, Jon J et al. (2006) Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. J Immunother 29:381-7

Showing the most recent 10 out of 103 publications